Basilea Pharmaceutica - Momentum continues
Basilea reported good momentum in H121 in all parts of the business. While total revenues declined to CHF54.2m (reflecting the phasing out of...
1.2k Views
Basilea Pharmaceutica - Multiple catalysts on the horizon
Basilea has provided an update on the three ongoing derazantinib Phase II trials (FIDES-01/02/03) that will define its utility in iCCA (bile duct...
690 Views
Basilea Pharmaceutica - A tale of two halves
Basilea reported good momentum in H120 as total revenues increased to CHF69.3m (+9.7%), highlighting ongoing growth in Cresemba (severe mould...
87 Views
Basilea Pharmaceutica - Cresemba sales the focus for future profitability
Basilea continues to build on its key franchises, Cresemba and Zevtera, with FY19 contributions from both increasing 39% to CHF114m, driven mainly...
593 Views
Basilea Pharmaceutica - 2020 vision on derazantinib in iCCA
Basilea Pharmaceutica is a revenue-generating biotech company that is on the cusp of breaking even (2021e) and sustainable profitability...
996 Views